GRFS - Grifols, S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.76
+0.01 (+0.05%)
At close: 4:00PM EDT

20.75 -0.01 (-0.05%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close20.75
Open20.91
Bid17.00 x 1000
Ask20.80 x 400
Day's Range20.73 - 21.10
52 Week Range19.79 - 25.18
Volume927,129
Avg. Volume607,322
Market Cap17.459B
Beta1.38
PE Ratio (TTM)34.86
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.42 (2.02%)
Ex-Dividend Date2017-12-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • With 21.50% Earnings Growth, Did Grifols SA. (BME:GRF) Outperform The Industry?
    Simply Wall St.8 days ago

    With 21.50% Earnings Growth, Did Grifols SA. (BME:GRF) Outperform The Industry?

    Today I will examine Grifols SA.’s (BME:GRF) latest earnings update (31 December 2017) and compare these figures against its performance over the past couple of years, in addition to howRead More...

  • Estimating The Fair Value Of Grifols SA. (BME:GRF)
    Simply Wall St.22 days ago

    Estimating The Fair Value Of Grifols SA. (BME:GRF)

    In this article I am going to calculate the intrinsic value of Grifols SA. (BME:GRF) using the discounted cash flows (DCF) model. If you want to learn more about thisRead More...

  • Is It Time To Buy Grifols SA. (BME:GRF) Based Off Its PE Ratio?
    Simply Wall St.29 days ago

    Is It Time To Buy Grifols SA. (BME:GRF) Based Off Its PE Ratio?

    Grifols SA. (BME:GRF) is trading with a trailing P/E of 23.2x, which is lower than the industry average of 28.5x. While this makes GRF appear like a great stock toRead More...

  • Can Grifols SA. (BME:GRF) Continue To Outperform Its Industry?
    Simply Wall St.last month

    Can Grifols SA. (BME:GRF) Continue To Outperform Its Industry?

    Grifols SA. (BME:GRF) delivered an ROE of 18.20% over the past 12 months, which is an impressive feat relative to its industry average of 17.90% during the same period. WhileRead More...

  • American City Business Journalslast month

    Grifols breaks ground on $120M Clayton facility

    Barcelona, Spain-based health care product and solutions giant Grifols has broken ground on a new $120 million facility at its Johnston County site, part of a $320 million investment in Clayton by 2022. The company's latest 150,000-square-foot addition in Clayton – expected to debut in 2022 – will be a purification and filling facility, used for making hemotherapy products, according to Grifols. Juan Antonio Garcia Diaz, president of Grifols Therapeutics LLC, called the facility "crucial to Grifols’ expansion plans at the Clayton site.

  • Grifols breaks ground on $120M Clayton facility
    American City Business Journalslast month

    Grifols breaks ground on $120M Clayton facility

    Barcelona, Spain-based health care product and solutions giant Grifols has broken ground on a new $120 million facility at its Johnston County site as it plans to invest another $320 million in Clayton by 2022.

  • Henry Schien to Distribute Grifols Product in United States
    Zackslast month

    Henry Schien to Distribute Grifols Product in United States

    We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

  • Stocks With Rising Relative Price Strength: Grifols
    Investor's Business Daily4 months ago

    Stocks With Rising Relative Price Strength: Grifols

    Grifols shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

  • Capital Cube4 months ago

    ETFs with exposure to Grifols SA : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Grifols SA Here are 5 ETFs with the largest exposure to GRFS-US. Comparing the performance and risk of Grifols SA with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Grifols SA : November 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Grifols SA Here are 5 ETFs with the largest exposure to GRFS-US. Comparing the performance and risk of Grifols SA with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
    Capital Cube6 months ago

    Grifols SA :GRFS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Grifols SA reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 1,264.20 million, Net Earnings of USD 160.84 million. Gross margins widened from 45.26% to 47.95% compared to the same period last year, operating (EBITDA) margins now 29.92% from 27.31%. Change in operating cash ... Read more (Read more...)

  • Should Value Investors Consider Grifols (GRFS) Stock Now?
    Zacks7 months ago

    Should Value Investors Consider Grifols (GRFS) Stock Now?

    Is Grifols (GRFS) a great pick from the value investor's perspective right now? Read on to know more.

  • 3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
    Zacks7 months ago

    3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

    The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

  • Grifols Shows Market Leadership With Jump To 82 RS Rating
    Investor's Business Daily7 months ago

    Grifols Shows Market Leadership With Jump To 82 RS Rating

    A Relative Strength Rating upgrade for Grifols shows improving technical performance.

  • GuruFocus.com8 months ago

    Grifols Is a Leader in High-Demand Plasma

    The Spanish company is the number 2 operator of plasma centers in the world

  • Stocks Flashing Renewed Technical Strength: Grifols
    Investor's Business Daily8 months ago

    Stocks Flashing Renewed Technical Strength: Grifols

    A Relative Strength Rating upgrade for Grifols shows improving technical performance.

  • When 'New' Means A Stock Hasn't Led The Market In A While
    Investor's Business Daily10 months ago

    When 'New' Means A Stock Hasn't Led The Market In A While

    Celgene and Grifols are former leaders, but enough time has passed to give them a new shine.

  • Should Value Investors Consider Grifols (GRFS) Stock Right Now?
    Zacks10 months ago

    Should Value Investors Consider Grifols (GRFS) Stock Right Now?

    Is Grifols a great pick from the value investor's perspective right now? Read on to know more.

  • Hologic Smashes Fiscal Q2 Sales Views, Beats On Profit By 4 Cents
    Investor's Business Daily11 months ago

    Hologic Smashes Fiscal Q2 Sales Views, Beats On Profit By 4 Cents

    Hologic crushed Wall Street's fiscal second-quarter revenue and profit expectations late Wednesday, led by double-digit growth.

  • VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y
    Zackslast year

    VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

    VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

  • Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
    Zackslast year

    Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View

    GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.